Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Blueprint Medicines | 144/A: Others
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 10-Q: Q3 2024 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Namouni Fouad
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Landsittel Michael
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Lee Philina
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
Blueprint Medicines | 10-Q: Q2 2024 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Carter Percy H.
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Rossi Christina
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Durso-Bumpus Debra
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Durso-Bumpus Debra
Blueprint Medicines | 4: Statement of changes in beneficial ownership of securities-Officer Durso-Bumpus Debra
Blueprint Medicines | 144: Notice of proposed sale of securities pursuant to Rule 144
No Data
No Data